Literature DB >> 8750580

Lack of prognostic significance of the monoclonal antibody Ki-S1, a novel marker of proliferative activity, in node-negative breast carcinoma.

P Bevilacqua1, P Verderio, M Barbareschi, E Bonoldi, P Boracchi, P Dalla Palma, G Gasparini.   

Abstract

In a series of 205 node-negative breast cancers (NNBC), we determined staining by the novel antibody Ki-S1, a marker of tumor cell proliferation, in order to test its association with other prognostic variables and its prognostic significance. Ki-S1 was determined in routinely formalin-fixed paraffin-embedded tumor samples. Ki-S1 gave a nuclear staining in the majority of the carcinomas (188 of 205), with percentages of reacting nuclei ranging from 2% to 90% (median value of 7%). In 107 tumors frozen sections were available to also assess the Ki-67 antibody. Among these, 94 had a nuclear staining of cancer cells ranging from 5% to 80% (median value of 7%). In 46 tumors we also determined the MIB-1 antibody. The percentage of MIB-1 nuclear staining ranged from 1% to 50% (median value of 20%). There was no significant relationship between Ki-S1 and the other two cell kinetic markers. Ki-S1 labeling was significantly associated only with tumor size (p = 0.03). With a median follow-up of 6 years, Ki-S1 had no significant prognostic value for either relapse-free survival (RFS) or overall survival (OS) (Ki-S1 as continuous logarithmic variable; p = 0.86 and p = 0.23, respectively). For RFS the following variables had a significant prognostic value: Ki-67 (< or = 10% vs > 10%; p = 0.037); progesterone receptor (PgR) expression (- vs+/++; p = 0.041); tumor size (pT1 vs pT2-3; p = 0.042) and grading (GI vs GII-III; p = 0.047). For OS, tumor size (p = 0.0044), age (continuous variable; p = 0.0060), and Ki-67 (p = 0.043) were significantly prognostic. In multivariate analysis (final model), only tumor size retained a significant and independent prognostic value for RFS (p = 0.0042). For OS, both tumor size (p = 0.0029) and age (< or = 55 years vs > 55 years; p = 0.041) retained significance in the multivariate model. In conclusion, Ki-S1 does not seem to have prognostic relevance in this series of NNBC. Possible hypotheses to explain this observation are discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8750580     DOI: 10.1007/bf01806494

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  29 in total

Review 1.  Immunohistochemical markers of cellular proliferation: achievements, problems and prospects.

Authors:  P A Hall; A L Woods
Journal:  Cell Tissue Kinet       Date:  1990-11

Review 2.  Clinical application of morphologic and immunocytochemical assessments of cell proliferation.

Authors:  M D Linden; F X Torres; J Kubus; R J Zarbo
Journal:  Am J Clin Pathol       Date:  1992-05       Impact factor: 2.493

3.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

Review 4.  Dangers of using "optimal" cutpoints in the evaluation of prognostic factors.

Authors:  D G Altman; B Lausen; W Sauerbrei; M Schumacher
Journal:  J Natl Cancer Inst       Date:  1994-06-01       Impact factor: 13.506

5.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.

Authors:  J Gerdes; U Schwab; H Lemke; H Stein
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

6.  The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4).

Authors:  E R Fisher; R M Gregorio; B Fisher; C Redmond; F Vellios; S C Sommers
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860

Review 7.  Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients.

Authors:  G Gasparini; F Pozza; A L Harris
Journal:  J Natl Cancer Inst       Date:  1993-08-04       Impact factor: 13.506

8.  Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast.

Authors:  U Veronesi; R Saccozzi; M Del Vecchio; A Banfi; C Clemente; M De Lena; G Gallus; M Greco; A Luini; E Marubini; G Muscolino; F Rilke; B Salvadori; A Zecchini; R Zucali
Journal:  N Engl J Med       Date:  1981-07-02       Impact factor: 91.245

9.  Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections.

Authors:  G Cattoretti; M H Becker; G Key; M Duchrow; C Schlüter; J Galle; J Gerdes
Journal:  J Pathol       Date:  1992-12       Impact factor: 7.996

10.  Cell kinetics as a prognostic marker in node-negative breast cancer.

Authors:  R Silvestrini; M G Daidone; G Gasparini
Journal:  Cancer       Date:  1985-10-15       Impact factor: 6.860

View more
  9 in total

1.  MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation.

Authors:  Einas M Yousef; Daniela Furrer; David L Laperriere; Muhammad R Tahir; Sylvie Mader; Caroline Diorio; Louis A Gaboury
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

2.  Comparison between different cell kinetic variables in human breast cancer.

Authors:  F Barzanti; M Dal Susino; A Volpi; D Amadori; A Riccobon; E Scarpi; L Medri; L Bernardi; S Naldi; M Aldi; M Gaudio; W Zoli
Journal:  Cell Prolif       Date:  2000-04       Impact factor: 6.831

3.  Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study.

Authors:  Dalal M Al Tamimi; Mohamed A Shawarby; Ayesha Ahmed; Ammar K Hassan; Amal A AlOdaini
Journal:  BMC Cancer       Date:  2010-05-21       Impact factor: 4.430

Review 4.  Prognostic value of proliferation in invasive breast cancer: a review.

Authors:  P J van Diest; E van der Wall; J P A Baak
Journal:  J Clin Pathol       Date:  2004-07       Impact factor: 3.411

5.  Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies.

Authors:  S Fasanella; E Leonardi; C Cantaloni; C Eccher; I Bazzanella; D Aldovini; E Bragantini; L Morelli; L V Cuorvo; A Ferro; F Gasperetti; G Berlanda; P Dalla Palma; M Barbareschi
Journal:  Diagn Pathol       Date:  2011-03-30       Impact factor: 2.644

6.  Association between Ki-67 expression and clinicopathological features in prognosis of breast cancer: A retrospective cohort study.

Authors:  Hosein Kamranzadeh; Reza Manouchehri Ardekani; Amir Kasaeian; Sanambar Sadighi; Somaye Maghsudi; Issa Jahanzad; Nasrollah Maleki
Journal:  J Res Med Sci       Date:  2019-04-26       Impact factor: 1.852

7.  EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.

Authors:  P Dubsky; M Filipits; R Jakesz; M Rudas; C F Singer; R Greil; O Dietze; I Luisser; E Klug; R Sedivy; M Bachner; D Mayr; M Schmidt; M C Gehrmann; C Petry; K E Weber; R Kronenwett; J C Brase; M Gnant
Journal:  Ann Oncol       Date:  2012-10-03       Impact factor: 32.976

8.  Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.

Authors:  Maggie C U Cheang; Stephen K Chia; David Voduc; Dongxia Gao; Samuel Leung; Jacqueline Snider; Mark Watson; Sherri Davies; Philip S Bernard; Joel S Parker; Charles M Perou; Matthew J Ellis; Torsten O Nielsen
Journal:  J Natl Cancer Inst       Date:  2009-05-12       Impact factor: 13.506

9.  Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.

Authors:  E de Azambuja; F Cardoso; G de Castro; M Colozza; M S Mano; V Durbecq; C Sotiriou; D Larsimont; M J Piccart-Gebhart; M Paesmans
Journal:  Br J Cancer       Date:  2007-04-24       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.